Benign Neoplasm of Salivary Gland Clinical Trial
Official title:
Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas
| Verified date | July 2020 |
| Source | Cairo University |
| Contact | yousra refaey |
| Phone | 01014458092 |
| yousrarefaey[@]yahoo.com | |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
in this resarch we will use ELISA Technique to estimate Human Transcriptional Activator(MYB) Expression .compare it by Immmunohistochemistry analysis of MYB Expression in the malignant and benign salivary gland tumor
| Status | Recruiting |
| Enrollment | 70 |
| Est. completion date | December 2021 |
| Est. primary completion date | September 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: . - Patients with clinically evident salivary gland tumors; malignant tumors will be recruited in group I - Benign tumors will be recruited in group II. Exclusion Criteria: - Subjects taking any drugs inducing any changes that could affect the salivary glands. - Pregnant females. - Subjects having any allergies, infectious or autoimmune diseases. - Subjects having any metabolic disorders that can be manifested with salivary gland swelling as diabetes mellitus. |
| Country | Name | City | State |
|---|---|---|---|
| Egypt | National Cancer Institute | Cairo |
| Lead Sponsor | Collaborator |
|---|---|
| Cairo University |
Egypt,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas | Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas. | two years |